MA33582B1 - Anticorps contre l'ectodomaine de erbb3 et leurs utilisations - Google Patents

Anticorps contre l'ectodomaine de erbb3 et leurs utilisations

Info

Publication number
MA33582B1
MA33582B1 MA34684A MA34684A MA33582B1 MA 33582 B1 MA33582 B1 MA 33582B1 MA 34684 A MA34684 A MA 34684A MA 34684 A MA34684 A MA 34684A MA 33582 B1 MA33582 B1 MA 33582B1
Authority
MA
Morocco
Prior art keywords
erbb3
antibodies
antigen
binding fragments
receptor
Prior art date
Application number
MA34684A
Other languages
Arabic (ar)
English (en)
Inventor
Birgit Schoeberl
Ulrik Nielsen
Michael Feldhaus
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43607614&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33582(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MA33582B1 publication Critical patent/MA33582B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet une nouvelle classe d'anticorps et leurs fragments de liaison à l'antigène qui se lient au domaine extracellulaire du récepteur erbb3 et inhibent différentes fonctions de erbb3. Par exemple, les anticorps et les fragments de liaison à l'antigène selon la présente invention sont capables de se lier au récepteur désigné erbb3 et d'inhiber la phosphorylation du récepteur médiée par un ligand de type egf. De tels anticorps et leurs fragments de liaison à l'antigène ont la caractéristique utile d'inhiber la prolifération des cellules cancéreuses exprimant erbb3.
MA34684A 2009-08-21 2012-03-12 Anticorps contre l'ectodomaine de erbb3 et leurs utilisations MA33582B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23579909P 2009-08-21 2009-08-21
PCT/US2010/046364 WO2011022727A2 (fr) 2009-08-21 2010-08-23 Anticorps contre l’ectodomaine de erbb3 et leurs utilisations

Publications (1)

Publication Number Publication Date
MA33582B1 true MA33582B1 (fr) 2012-09-01

Family

ID=43607614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34684A MA33582B1 (fr) 2009-08-21 2012-03-12 Anticorps contre l'ectodomaine de erbb3 et leurs utilisations

Country Status (21)

Country Link
EP (1) EP2467164A2 (fr)
JP (1) JP5752687B2 (fr)
KR (1) KR20120059568A (fr)
CN (1) CN103002912A (fr)
AU (1) AU2010284018C1 (fr)
BR (1) BR112012003809A2 (fr)
CA (1) CA2771744A1 (fr)
CR (1) CR20120108A (fr)
DO (1) DOP2012000044A (fr)
EA (1) EA201200195A1 (fr)
EC (1) ECSP12011740A (fr)
IL (1) IL218097A0 (fr)
IN (1) IN2012DN01518A (fr)
MA (1) MA33582B1 (fr)
MX (1) MX336091B (fr)
NI (1) NI201200027A (fr)
PE (1) PE20121585A1 (fr)
SG (1) SG178509A1 (fr)
TN (1) TN2012000057A1 (fr)
WO (1) WO2011022727A2 (fr)
ZA (1) ZA201201195B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (fr) 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Anticorps contre erbb3 et leur utilisation
DK3351558T3 (da) * 2009-11-13 2020-06-02 Daiichi Sankyo Europe Gmbh Materiale og fremgangsmåder til behandling eller forebyggelse af her-3-relaterede sygdomme
EP2516469B1 (fr) 2009-12-22 2016-03-30 Roche Glycart AG Anticorps anti-HER3 et leurs utilisations
CN102858335B (zh) 2010-03-11 2015-04-15 梅里麦克制药股份有限公司 Erbb3抑制剂在三阴性乳腺癌和基底样乳腺癌治疗中的用途
BR112012025730B1 (pt) 2010-04-09 2020-12-08 Aveo Pharmaceuticals, Inc anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão
KR102027011B1 (ko) 2010-08-20 2019-09-30 노파르티스 아게 표피 성장 인자 수용체 3 (ｈｅｒ3)에 대한 항체
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
IT1402149B1 (it) * 2010-10-04 2013-08-28 Ist Fisioterap Ospitalroma Uso di un fosfopeptide in grado di bloccare l interazione her3/p85 per il trattamento dei tumori iperesprimenti her2.
JP6033783B2 (ja) * 2010-11-01 2016-11-30 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ Ｐａｎ−ｈｅｒ抗体組成物
US8476409B2 (en) 2011-04-19 2013-07-02 Merrimack Pharmaceuticals, Inc. Bispecific anti-IGF-1R and anti-ErbB3 antibodies
JPWO2012176779A1 (ja) * 2011-06-20 2015-02-23 協和発酵キリン株式会社 抗ｅｒｂＢ３抗体
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
IN2014CN03042A (fr) 2011-09-30 2015-07-03 Regeneron Pharma
AU2012318541B2 (en) 2011-10-06 2018-04-12 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
EP2788377B1 (fr) * 2011-11-09 2019-01-23 The UAB Research Foundation Anticorps her3 et utilisations de ceux-ci
EP3590538A1 (fr) 2011-12-05 2020-01-08 Novartis AG Anticorps dirigés contre le récepteur 3 du facteur de croissance épidermique (her3)
WO2013124297A1 (fr) * 2012-02-22 2013-08-29 U3 Pharma Gmbh Composition d'une protéine de liaison d'hb-egf et d'un inhibiteur de l'egfr
AR094403A1 (es) 2013-01-11 2015-07-29 Hoffmann La Roche Terapia de combinación de anticuerpos anti-her3
US20160232293A1 (en) * 2013-10-17 2016-08-11 Sanford-Burnham Medical Research Institute Drug sensitivity biomarkers and methods of identifying and using drug sensitivity biomarkers
EP3087394A2 (fr) 2013-12-27 2016-11-02 Merrimack Pharmaceuticals, Inc. Profils de biomarqueur pour prédire les résultats d'une thérapie cancéreuse utilisant des inhibiteurs d'erbb3 et/ou des chimiothérapies
NZ724013A (en) * 2014-02-28 2019-11-29 Merus Nv Antibodies that bind egfr and erbb3
CN110642952B (zh) * 2014-08-14 2021-05-25 上海生物制品研究所有限责任公司 抗her3抗体、其制法及其应用
WO2016038610A1 (fr) 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Compositions et procédés de traitement d'un cancer résistant à un inhibiteur de la tyrosine kinase (tki)
WO2016038609A1 (fr) * 2014-09-08 2016-03-17 Yeda Research And Development Co. Ltd. Anticorps anti-her3 et leurs utilisations
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017069628A2 (fr) 2015-10-23 2017-04-27 Merus N.V. Molécules de liaison inhibant la croissance de cancer
US11780925B2 (en) 2017-03-31 2023-10-10 Merus N.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment of cells that have an NRG1 fusion gene
EP3665200A4 (fr) 2017-08-09 2021-04-28 University of Saskatchewan Agents de liaison à her3 et utilisations associées
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet
GB201804094D0 (en) * 2018-03-14 2018-04-25 Ultrahuman Thirteen Ltd ERBB3 Binding agents
JP2021534811A (ja) * 2018-06-22 2021-12-16 シーアールディー ファーマシューティカルズ インコーポレイティド 抗ｈｅｒ３抗体およびその用途
AU2021360625A1 (en) * 2020-10-14 2023-06-01 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-her3 antibody and anti-her3 antibody-drug conjugate and medical use thereof
WO2023198138A1 (fr) * 2022-04-13 2023-10-19 上海翰森生物医药科技有限公司 Anticorps ou fragment de liaison à l'antigène de celui-ci et son utilisation médicale

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2129396B1 (fr) * 2007-02-16 2013-08-21 Merrimack Pharmaceuticals, Inc. Anticorps contre erbb3 et leur utilisation

Also Published As

Publication number Publication date
AU2010284018C1 (en) 2015-10-15
CR20120108A (es) 2012-06-05
KR20120059568A (ko) 2012-06-08
TN2012000057A1 (en) 2013-09-19
ECSP12011740A (es) 2013-02-28
CA2771744A1 (fr) 2011-02-24
AU2010284018A1 (en) 2012-03-22
ZA201201195B (en) 2015-07-29
JP2013506622A (ja) 2013-02-28
MX336091B (es) 2016-01-08
PE20121585A1 (es) 2012-11-29
SG178509A1 (en) 2012-04-27
IN2012DN01518A (fr) 2015-06-05
AU2010284018B2 (en) 2014-06-05
CN103002912A (zh) 2013-03-27
EA201200195A1 (ru) 2012-12-28
DOP2012000044A (es) 2012-06-30
WO2011022727A3 (fr) 2013-06-27
IL218097A0 (en) 2012-04-30
EP2467164A2 (fr) 2012-06-27
WO2011022727A2 (fr) 2011-02-24
MX2012002172A (es) 2012-05-29
BR112012003809A2 (pt) 2019-09-24
NI201200027A (es) 2013-01-29
JP5752687B2 (ja) 2015-07-22

Similar Documents

Publication Publication Date Title
MA33582B1 (fr) Anticorps contre l'ectodomaine de erbb3 et leurs utilisations
EA200901119A1 (ru) АНТИТЕЛА ПРОТИВ ErbB3 И ИХ ПРИМЕНЕНИЕ
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
PH12018501778A1 (en) Antibodies to tigit
MA43186B1 (fr) Anticorps se liant spécifiquement à pd-1 et leurs utilisations
WO2020039321A3 (fr) Anticorps anti-gdf15, compositions et procédés d'utilisation
MX2019012953A (es) Anticuerpo biespecifico contra ox40 y ctla-4.
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
EP2560994A4 (fr) Anticorps anti-cd122
UA113388C2 (xx) ЗАСТОСУВАННЯ АНТИТІЛА ПРОТИ с-МЕТ
CL2012000254A1 (es) Anticuerpo aislado de unión a antígeno que se une a proteína atenuante de linfocitos b y t (btla); ácido nucleico que lo codifica; composición que comprende a dicho anticuerpo; y vector de expresión.
NZ591153A (en) Anti-cd5 antibodies
MX2010005031A (es) Anticuerpos de axl.
MX369148B (es) Agentes de unión kir3dl2.
MX344971B (es) Anticuerpos anti-ctla4 humanizados.
TN2009000182A1 (en) Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MX2009005361A (es) Anticuerpos monoclonales neutralizantes contra el receptor de nogo-66 (ngr) y usos de los mismos.
MX2022006578A (es) Anticuerpos especificos para cd47, pd-l1 y sus usos.
PH12021550361A1 (en) Anti-avb8 antibodies and compositions and uses thereof
MA47221A1 (fr) Anticorps monoclonal à pd-l1
IN2014CN04374A (fr)
EA202092448A1 (ru) Axl-специфичные антитела для лечения онкологических заболеваний
UA112752C2 (uk) Лікарський засіб та метод блокування утворення або посилення знищення білка p24
MA44909A (fr) Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
MX2022007464A (es) Composiciones biofarmaceuticas y metodos relacionados.